As the football transfer window closes, we announce £500k of new signings who'll join our lab teams fighting prostate cancer around the UK.

1 Sep 2015

With the transfer deadline about to pass, we're pleased to announce the five new PhD students we've signed to Men United who will help continue our vital research into prostate cancer in labs across the UK.

With support already pledged from the Mike Gooley Trailfinders Charity, the Tom and Sheila Springer Charity and the Holbeck Charitable Trust, Men United has used a very respectable transfer budget of £500,000. Each of our new signings will be tackling our formidable opposition from a different angle, working on a range of cutting-edge science to improve prostate cancer treatment.

New researchers in the lab

Salpie Nowinski – signed for Dr Anita Grigoriadis’ team at King’s College London

Salpie will combine clinical and genetic information to find specific DNA changes that can identify men whose prostate cancer does not need treatment, and men who should be treated immediately.

Millie McAllister – signed for Dr Joanne Edwards' team at the University of Glasgow

Millie will look at the molecular differences in prostate cancer samples from men who did, and didn’t, respond well to advanced prostate cancer treatments, such as Abiraterone and Enzalutamide. She is trying to find ways to predict in advance which drugs will work best for each man.  

Natalie Owen – signed for Dr Jonathan Coulter's team at Queen’s University Belfast

Natalie will attempt to improve prostate cancer cells’ sensitivity to radiotherapy by attaching tiny gold specks called gold nanoparticles to the membrane that surrounds the cells.

Eva Kounatidou – signed for Dr Luke Gaughan at Newcastle University

Eva will explore the detailed workings of the Androgen Receptor (AR), a protein that drives prostate cancer growth. She’ll study the way it changes when hormone therapy stops working to see if this opens up any possibilities for new advanced prostate cancer treatments.

Mitchell Clarke – signed for Dr Justin Sturge at the University of Hull

Mitchell will refine and test a system to monitor the change between inert and aggressive prostate cancer. Dr Sturge’s team first developed this system, called ENDOGLOW, during a previous Prostate Cancer UK-funded project. He hopes Mitchell's project will show that it can be used to monitor disease progression by giving a visual indication of if or when a prostate cancer needs treatment.

All in all, this has all the markings of a development squad with a bright future ahead of them – for themselves, and for the men with prostate cancer they’re working to benefit. We’ll keep you updated with the latest results from these newest signings, and our other lab-based team mates, as their projects progress.

comments powered by Disqus